Rubius Therapeutics to Announce Second Quarter 2019 Financial Results

CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. RUBY, a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced plans to report second quarter 2019 financial results on Tuesday, August 13, 2019, before market open.

The company will not be conducting a teleconference in conjunction with its financial results press release.

About Rubius Therapeutics



Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM^® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius' initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. For more information, visit www.rubiustx.com, or follow us on Twitter and LinkedIn.



Contact:

Lori Melançon

Vice President, Corporate Communications and Investor Relations

+1 (617) 949-5296

lori.melancon@rubiustx.com

Media Contact: 

Dan Budwick

1AB

+1 (973) 271-6085

dan@1abmedia.com